TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07704515: A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GKL-006Allo Injection in Patients With Solid Tumors

Sponsor: Beijing Gene Key Life Technology Co., Ltd · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 27 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT07704515 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07704515 Rescue Dossier →